相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution
R. Kleef et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Tumor Immunology and Tumor Evolution: Intertwined Histories
Jerome Galon et al.
IMMUNITY (2020)
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses
Patricia M. Santos et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Prognostic value of tertiary lymphoid structure and tumour infiltrating lymphocytes in oral squamous cell carcinoma
Qunxing Li et al.
INTERNATIONAL JOURNAL OF ORAL SCIENCE (2020)
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
Tanja Lovgren et al.
ONCOIMMUNOLOGY (2020)
Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer
Lukas W. Pfannenstiel et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
Anna V. Tinker et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?
Matthew Zibelman et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs
Charles S. Tannenbaum et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Thorbald van Hall et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Cytokines in clinical cancer immunotherapy
Pedro Berraondo et al.
BRITISH JOURNAL OF CANCER (2019)
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma
Hanjie Li et al.
CELL (2019)
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Theodore S. Nowicki et al.
CLINICAL CANCER RESEARCH (2019)
CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Masao Hashimoto et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Michael B. Atkins et al.
CLINICAL CANCER RESEARCH (2018)
Cutaneous MelanomaA Long Road from Experimental Models to Clinical Outcome: A Review
Dorina Coricovac et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity
Victor H. Engelhard et al.
JOURNAL OF IMMUNOLOGY (2018)
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Daniela S. Thommen et al.
NATURE MEDICINE (2018)
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
Norbert Vey et al.
Oncotarget (2018)
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Remy Thomas et al.
FRONTIERS IN IMMUNOLOGY (2018)
Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
Adriana Albini et al.
FRONTIERS IN IMMUNOLOGY (2018)
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander et al.
NATURE MEDICINE (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman et al.
CELL (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Anna Passarelli et al.
ONCOTARGET (2017)
Tuning cancer fate: the unremitting role of host immunity
B. Cali et al.
OPEN BIOLOGY (2017)
Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
Hassan Sadozai et al.
FRONTIERS IN IMMUNOLOGY (2017)
B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment
Giulia Chiaruttini et al.
ONCOIMMUNOLOGY (2017)
Tumor-derived exosomes induce CD8+ T cell suppressors
Brian T. Maybruck et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Fade Mahmoud et al.
CANCER BIOLOGY & THERAPY (2017)
Targeting neoantigens to augment antitumour immunity (vol 17, pg 209, 2017)
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
Mark A. Exley et al.
CLINICAL CANCER RESEARCH (2017)
Melanoma antigens and related immunological markers
Jacob Pitcovski et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)
P. Saiag et al.
ANNALS OF ONCOLOGY (2016)
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Ajjai Alva et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Andy J. Minn et al.
CELL (2016)
Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma
Sarah A. Weiss et al.
HUMAN PATHOLOGY (2016)
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito et al.
NATURE MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Nayoung Lee et al.
PATHOLOGY (2016)
Understanding Immune Cells in Tertiary Lymphoid Organ Development: It Is All Starting to Come Together
Gareth W. Jones et al.
FRONTIERS IN IMMUNOLOGY (2016)
Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention
Catherine Sautes-Fridman et al.
FRONTIERS IN IMMUNOLOGY (2016)
Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients
Yumi Nonomura et al.
ONCOIMMUNOLOGY (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Sjoerd H. van der Burg et al.
NATURE REVIEWS CANCER (2016)
Regulatory circuits of T cell function in cancer
Daniel E. Speiser et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
R. Gutzmer et al.
ESMO OPEN (2016)
Metastatic Melanoma - A Review of Current and Future Treatment Options
Emanual Maverakis et al.
ACTA DERMATO-VENEREOLOGICA (2015)
The MAGE protein family and cancer
Jenny L. Weon et al.
CURRENT OPINION IN CELL BIOLOGY (2015)
The expanding family of regulatory B cells
Claudia Mauri et al.
INTERNATIONAL IMMUNOLOGY (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
Jo Marie Tran Janco et al.
JOURNAL OF IMMUNOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
T-cell exhaustion in the tumor microenvironment
Y. Jiang et al.
CELL DEATH & DISEASE (2015)
Characterization of tumor infiltrating Natural Killer cell subset
Inbar Levi et al.
ONCOTARGET (2015)
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
Bin Shang et al.
SCIENTIFIC REPORTS (2015)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
Human Tumor Antigens and Cancer Immunotherapy
Nathalie Vigneron
BIOMED RESEARCH INTERNATIONAL (2015)
Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma
I. Chevolet et al.
ONCOIMMUNOLOGY (2015)
Multiple molecular pathways in melanomagenesis: characterization of therapeutic targets
Giuseppe Palmieri et al.
FRONTIERS IN ONCOLOGY (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
The immune escape in melanoma: role of the impaired dendritic cell function
Marco Tucci et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Duality of the Immune Response in Cancer: Lessons Learned from Skin
Terry R. Medler et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Clinical use of dendritic cells for cancer therapy
Sebastien Anguille et al.
LANCET ONCOLOGY (2014)
Prognostic Value of Tumor-Infiltrating FoxP3+ T Cells in Gastrointestinal Cancers: A Meta Analysis
Yong Huang et al.
PLOS ONE (2014)
T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
Ignacio Melero et al.
CANCER DISCOVERY (2014)
T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?
Daniel E. Speiser et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma
Carole Yolande Perrot et al.
ANNALS OF DERMATOLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Reassessing target antigens for adoptive T-cell therapy
Christian S. Hinrichs et al.
NATURE BIOTECHNOLOGY (2013)
Development of Allogeneic NK Cell Adoptive Transfer Therapy in Metastatic Melanoma Patients: In Vitro Preclinical Optimization Studies
Michal J. Besser et al.
PLOS ONE (2013)
Immunosuppressive Mechanisms of Regulatory Dendritic Cells in Cancer
Galina V. Shurin et al.
CANCER MICROENVIRONMENT (2013)
Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
Sine Hadrup et al.
CANCER MICROENVIRONMENT (2013)
FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis
Miki Takenaka et al.
MOLECULAR AND CLINICAL ONCOLOGY (2013)
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram et al.
BLOOD (2012)
The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia
Zhao Zhi-Gang et al.
EUROPEAN JOURNAL OF CANCER (2012)
Cancer classification using the Immunoscore: a worldwide task force
Jerome Galon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Pegylated Interferon for the Adjuvant Treatment of Melanoma: FDA Approved, but What Is Its Role?
Vernon K. Sondak et al.
ONCOLOGIST (2012)
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
Jane L. Messina et al.
SCIENTIFIC REPORTS (2012)
Cross-presentation by dendritic cells
Olivier P. Joffre et al.
NATURE REVIEWS IMMUNOLOGY (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
Stable IL-10: A New Therapeutic that Promotes Tumor Immunity
Michele W. L. Teng et al.
CANCER CELL (2011)
Immunomodulatory cytokines as therapeutic agents for melanoma
Courtney Nicholas et al.
IMMUNOTHERAPY (2011)
Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial
Henrik Schmidt et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy
Claude Sportes et al.
CLINICAL CANCER RESEARCH (2010)
Development and homeostasis of dendritic cells
Kang Liu et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Origin and development of dendritic cells
Kang Liu et al.
IMMUNOLOGICAL REVIEWS (2010)
Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis
Xian-Zong Ye et al.
JOURNAL OF GENETICS AND GENOMICS (2010)
Tolerogenic Dendritic Cells Induce CD4+CD25hiFoxp3+ Regulatory T Cell Differentiation from CD4+CD25-/loFoxp3- Effector T Cells
Hui Huang et al.
JOURNAL OF IMMUNOLOGY (2010)
An Overview of Cytokines and Cytokine Antagonists as Therapeutic Agents
Raymond P. Donnelly et al.
CYTOKINE THERAPIES: NOVEL APPROACHES FOR CLINICAL INDICATIONS (2009)
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
C. Marcela Diaz-Montero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via L-Arginine Metabolism
Lyse A. Norian et al.
CANCER RESEARCH (2009)
Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
Han Chong Toh et al.
CLINICAL CANCER RESEARCH (2009)
Tumor-induced senescent T cells with suppressor function: A potential form of tumor immune evasion
Carolina L. Montes et al.
CANCER RESEARCH (2008)
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
Sylvia Adams et al.
JOURNAL OF IMMUNOLOGY (2008)
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells
Pratima Sinha et al.
JOURNAL OF IMMUNOLOGY (2008)
The known unknowns of antigen processing and presentation
Jatin M. Vyas et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Immunotherapy of cancer by IL-12-based cytokine combinations
Jonathan M. Weiss et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
PD-1 and its ligands in T-cell immunity
Mary E. Keir et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Immune surveillance of tumors
Jeremy B. Swann et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Indoleamine 2,3-dioxygenase in immune suppression and cancer
Alexander J. Muller et al.
CURRENT CANCER DRUG TARGETS (2007)
A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer
Mirjam. T. Epping et al.
CANCER RESEARCH (2006)
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes:: results of thefirst phase I clinical trial
B Escudier et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Immunoregulatory T cells in tumor immunity
M Terabe et al.
CURRENT OPINION IN IMMUNOLOGY (2004)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
YE Latchman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
IDO expression by dendritic cells: Tolerance and tryptophan catabolism
AL Mellor et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity
T Ramirez-Montagut et al.
ONCOGENE (2003)
The use of dendritic cells in cancer immunotherapy
G Schuler et al.
CURRENT OPINION IN IMMUNOLOGY (2003)
Natural selection of tumor variants in the generation of tumor escape phenotypes
HT Khong et al.
NATURE IMMUNOLOGY (2002)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Generation of dendritic cell-based vaccines for cancer therapy
G Reinhard et al.
BRITISH JOURNAL OF CANCER (2002)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
A fresh look at tumor immunosurveillance and immunotherapy
MJ Smyth et al.
NATURE IMMUNOLOGY (2001)
分享论文
